LEP and metabolic disease: Given the role of IGF-1 in metabolic regulation, we hypothesize that improvements in insulin sensitivity and liver histopathology following exogenous leptin therapy would be associated with changes in IGF-1 levels, which may correlate with improvements in metabolic disease.